

LINEE GUIDA VALUTAZIONE PROTOCOLLI

Fase in remoto

I protocolli di studio sono stati caricati nel sistema operativo del Ministero della Salute associati ad un codice identificativo (in base ai criteri NIH) per consentire al revisore di individuare il progetto pertinente alla sua expertise.

I criteri applicati per definire il punteggio sono identificati in base alle linee guida del Ministero della Salute, che si riassumono qui di seguito.

Sono identificati 5 criteri principali di valutazione:

- Rilevanza scientifica
- Metodologia/disegno di studio, bibliografia di riferimento
- Livello di innovatività
- Organizzazione/centro sperimentale
- Principal investigator (qualifica professionale)

Per ciascun criterio è applicato un punteggio da 1 a 9, con 1 equivalente ad eccezionale e 9 a scadente. La somma dei punteggi per i cinque aspetti considerati ha portato alla definizione del punteggio finale.

In base a tali criteri, il punteggio fino a 5 corrisponde all'eccezionalità, il punteggio fino a 12 corrisponde all'eccellenza, il punteggio fino a 15 corrisponde al livello molto buono/quasi eccellente.

La valutazione è stata svolta in cieco dai due revisori in remoto, uno dei quali con ruolo di coordinatore.

In seguito all'emissione del relativo punteggio da parte dei due valutatori, il coordinatore ha verificato la corrispondenza dei punteggi. In caso di accordo, il punteggio è stato considerato definitivo. In caso di disaccordo, si avvia una discussione in remoto tra i due revisori (face to face). In caso di accordo raggiunto durante la discussione, questo corrisponde al punteggio finale; in caso di disaccordo, i due punteggi rimangono in memoria con i relativi giudizi.

Alla fine di questa fase si è raggiunto il seguente esito:

63 protocolli:	accordo nella doppia valutazione in remoto
22 protocolli	disaccordo/valutazione non definitiva

Study Session

La fase finale di valutazione e definizione della graduatoria dei vincitori si è svolta mediante una Study Session, composta da esperti italiani e stranieri, nominata dal Ministero della Salute. La Study Session, dopo aver acquisito i punteggi ed i giudizi relativi alla valutazione in remoto, ha verificato la congruenza dei giudizi in accordo. Successivamente i componenti della Study Session, suddivisi in coppie, hanno completato le valutazioni incomplete o in disaccordo, applicando lo stesso approccio iniziale in cieco. Sono stati discussi in plenaria i casi con maggiore differenza di giudizio fra i due revisori della prima fase. Alla fine dei lavori la Study Session ha quindi definito i punteggi che hanno portato alla costituzione della graduatoria finale.

PRINCIPAL INVESTIGATOR	CODICE FARM	TITOLO	AREA	TEMATICA	ISTITUZIONE PROPONENTE	PUNTEGGIO
GERARDO NARDONE	FARM12R9HF	Efficacy and safety of mesalazine and rifaximin, alone or as extemporary combination for primary prevention of diverticulitis in patients with symptomatic uncomplicated diverticular disease of colon: multi-centre, randomised, double-blind, double - dummy, parallel group, placebocontrolled stud (merisud study)	B	7	Università Federico II di Napoli	8,00
GIORGIO VITTORIO SCAGLIOTTI	FARM12TS4L	Randomized Phase III Multicenter Trial of Customized Chemotherapy versus Standard of Care for 1st Line Treatment of Elderly Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC)	A	1	Universita' di Torino	8,00
SILVIO DANESE	FARM12YYRS	Comparison between two therapeutic strategies for the maintenance of clinical and endoscopic remission in patients with ulcerative colitis treated by infliximab	A	1	Istituto di ricovero and cura a carattere scientifico Humanitas, centro per le malattie infiammatorie croniche dell'intestino – UOC gastroenterologia ed endoscopia digestiva	8,00
STEFANO BOMBARDIERI	FARM12LTAT	The role of anti TNF alpha agents in Behçet's disease refractory to standard of care therapies: multicenter randomized controlled prospective parallel group single-blind trial to evaluate the 6-month effectiveness of either infliximab or adalimumab	A	1	Unità di Reumatologia, Dipartimento di Medicina Interna, Università di Pisa	8,50
GIANCARLO COMI	FARM12N3TX	Discontinuation of first-line disease modifying treatment (DMT) in long-term full responders MS patients: a multicentre randomized clinical trial	A	1	Fondazione Centro San Raffaele, Dipartimento di Neurologia, Milano	8,50
ANTONELLA D'ARMINIO MONFORTE	FARM12FEXH	Impact on bone mineral density (bmd) of tdf-sparing antiretroviral regimens in HIV-positive menopausal women affected by osteopenia: the Tenofovir Sparing Strategy (TESS) study	A	8	Azienda Ospedaliera San Paolo, Unità Malattie Infettive e Tropicali, Milano	9,00

PRINCIPAL INVESTIGATOR	CODICE FARM	TITOLO	AREA	TEMATICA	ISTITUZIONE PROPONENTE	PUNTEGGIO
MARIA GRAZIA MARCIANI	FARM12PW7R	Effects of antidepressant treatment with agomelatine on patients affected by depression and epilepsy. A double blind randomized study with active control (escitalopram) with parallel groups	A	6	Università di Roma Tor Vergata Dipartimento di Medicina dei Sistemi	9,00
LAURA BAZZICHI	FARM125FKN	Phase 4, multicenter randomised study, aimed at evaluating the maintenance of remission after 6, 12, 18 and 24 months from suspension of TNF-alpha therapies (adalimumab, etanercept, infliximab, certolizumab pegol, golimumab) in rheumatoid arthritis (RA) patients	A	1	Unità di Reumatologia, Dipartimento di Medicina Interna, Università di Pisa	9,00
VITO MARCO RANIERI	FARM12MNXK	Oxygen therapy with pressurized system (Continuous positive airway pressure: CPAP) versus standard oxygen administration to reduce the respiratory complication after cardiac surgery: Multicentric Randomized Clinical Trial	A	3	Università di Torino, Dipartimento di anestesia e medicina d'urgenza, Ospedale Città della Salute e della Scienza	9,00
ALBERTO ZANGRILLO	FARM12MAEF	Continuous infusion versus intermittent administration of meropenem in critically ill patients. A multicenter randomized double blind trial	A	3	Fondazione Centro San Raffaele, Dipartimento di anestesia e medicina d'urgenza	9,50
MAURIZIO PACIARONI	FARM12L9JE	PREvention of VENous Thromboembolism In Hemorrhagic Stroke patients: PREVENTIHS study	A	5	Ospedale Santa Maria della Misericordia, Dipartimento di Medicina intera, Divisione di cardiologia e unità coronarica	9,50
PAOLO PALANGE	FARM12H2MT	Anti-muscarinic drugs as a preventive treatment of exercise-induced asthma in children and adults	B	6	Università di Roma "La Sapienza", Dipartimento di sanità pubblica e malattie infettive.	10,00
ANDREA FRUSTACI	FARM12JCXN	Multicenter randomized study on the efficacy of immunosuppression in patients with virus-negative inflammatory cardiomyopathy	A	1	Ospedale "Umberto I", Università di Roma "La Sapienza"	10,00

PRINCIPAL INVESTIGATOR	CODICE FARM	TITOLO	AREA	TEMATICA	ISTITUZIONE PROPONENTE	PUNTEGGIO
LAURA AMATO	FARM12SYA9	Systematic Review to evaluate the efficacy, acceptability and safety of second generation antipsychotics for the treatment of unipolar and bipolar depression	B	6	Asl di Roma E, Dipartimento di epidemiologia, gruppo Cochrane droga e alcol	10,25
CARLO ALBERTO SCIRE'	FARM12R5ET	Open-label, randomized controlled trial comparing tocilizumab to anti-TNF treatment and discovery of biomarkers for treatment selection in rheumatoid arthritis patients with inadequate response to a first anti-TNF	A	1	Associazione/Società Scientifica o di ricerca non a fini di lucro; Società Italiana Di Reumatologia, Milano	11,00
CRISTINA BOSETTI	FARM12XLS5	Evaluation of (cardio and cerebrovascular) adverse events in users of incretin-based therapies versus other antidiabetic drugs using the healthcare utilization databases of the Lombardy Region	B	3	IRCCS – Istituto di ricerche farmacologiche "Mario Negri", Dipartimento di epidemiologia, Milano	11,25
ALBERICO LUIGI CATAPANO	FARM12KSBT	Effectiveness of informative and/or educational interventions aimed at improving the appropriate use of drugs designed for general practitioners and their patients	B	5	Università di Milano, Dipartimento di farmacologia e scienze biomolecolari, Centro di epidemiologia e farmacologia preventiva (Sefap)	11,50
VALERIO DE STEFANO	FARM12Y8HH	Novel strategies of antithrombotic prophylaxis in patients with essential thrombocythemia at high risk of cardiovascular events: comparison of different dosing regimens of administration of low-dose acetylsalicylic acid	A	5	Ospedale Universitario "Agostino Gemelli", Istituto di ematologia	11,50
GIOVANNI BRANDI	FARM12TZ3N	A multicenter, randomized, open-label phase 3 study of two anti-angiogenic strategies in advanced hepatocellular carcinoma patients with cross-over at first-line failure: metronomic Capecitabine/Sorafenib (Arm A) vs Sorafenib/metronomic Capecitabine (Arm B)	A	1	Azienda ospedaliera-universitaria S. Orsola-Malpighi, Università di Bologna, Dipartimento di medicina specialistica diagnostica e sperimentale (DIMES)	11,50
ANDREA ROCCA	FARM125RHR	Randomized clinical trial of concomitant chemo-endocrine therapy versus chemotherapy followed by endocrine therapy as first line treatment of luminal B metastatic breast cancer	A	1	Istituto Scientifico Romagnolo per lo studio e la cura dei tumori	11,50

PRINCIPAL INVESTIGATOR	CODICE FARM	TITOLO	AREA	TEMATICA	ISTITUZIONE PROPONENTE	PUNTEGGIO
ENZO BERARDESCA	FARM1275JK	Monitoring The Effectiveness And Safety Of Biological Drugs For Treatment Of Psoriasis Through Evaluation Of Clinical And Biological Markers	A	1	Istituto di ricovero e cura a carattere scientifico (IRCCS), Istituto dermatologico San Gallicano, Dipartimento di dermatologia clinica	12,00
TIZIANA BOVE	FARM12JFX9	Frusemide increases mortality in critically ill patients with or at risk for acute kidney injury. A meta analysis of randomized trials	B	6	Fondazione Centri San Raffaele Milano	12,00
ERSILIA LUCENTEFORTE	FARM12T4BK	Safety of Long-acting Nitrates, Ivabradine, Nicorandil and Ranolazine to treat or prevent stable angina: systematic review and meta-analysis	B	6	Univerità di Firenze, Dipartimento di neuroscienze, Psicologia, Area del farmaco e Salute del bambino	12,00
ENRICO VASILE	FARM122SLM	Phase III randomized trial comparing FOLFOXIRI and Gemcitabine as adjuvant treatment for patients with resected pancreatic cancer	A	1	Azienda ospedaliero-universitaria pisana, Dipartimento di oncologia dei trapianti e delle nuove tecnologie in medicina, U.O. oncologia 2 universitaria, Polo oncologico	12,00
MATILDE LEONARDI	FARM12RHZ9	Title: Multicenter, randomized controlled trial of Amantadine and Donepezil versus Placebo to improve behavioural functions in patients in Vegetative State and Minimally Conscious State	A	6	Fondazione IRCCS Istituto Neurologico C. Besta, Unità di neurologia, Salute Pubblica e Disabilità.	12,50
LEONARDO PANTONI	FARM12TZ9H	Title: Efficacy and safety of Acetazolamide and aspirin in CADASIL patients	A	7	Azienda Ospedaliero Universitaria Careggi	12,50
ANDREA MESSORI	FARM12JS7Y	Title: Long-term outcomes of prophylactic vs on-demand treatment for severe haemophilia A: meta-analysis and meta-regression of observational and randomised controlled trials.	B	6	Servizio Sanitario Regionale, Centro ESTAV Unità HTA, Prato	12,50
GIOVANNI GAMBASSI	FARM12HZMH	Rifaximin and mesalazine for the treatment of diverticulitis recurrence in the elderly – the FDA (Farmaci e Diverticolosi nell'Anziano) study	B	7	Università Cattolica del Sacro Cuore	12,75

PRINCIPAL INVESTIGATOR	CODICE FARM	TITOLO	AREA	TEMATICA	ISTITUZIONE PROPONENTE	PUNTEGGIO
MARIO ANGELICO	FARM12TCYT	PegINF add-on in HBeAg negative patients with Chronic Hepatitis B treated with nucleos(t)ide analogs: assessment of patients who may discontinue therapy and identification of virological, genetic and epigenetic markers of response and risk of hepatocellular carcinoma	A	1	Unità di Gastroenterologia, Dipartimento di Medicina Sperimentale e Chirurgia, Università di Roma Tor Vergata	13,00
MARIO MANDALA'	FARM125FTN	Genomic-based optimization of first-line treatment in patients with wild-type kras advanced colorectal carcinoma: multicenter, randomized clinical trial comparing FOLFIRI+cetuximab and FOLFIRI+bevacizumab	A	1	Azienda Ospedaliera Papa Giovanni XXIII, Dipartimento di Oncologia e Ematologia, USC di Oncologia Medica - Bergamo	13,00
EMILIO SACCHETTI	FARM125SMN	Pharmacological treatment of post-partum depression and post-partum psychosis: systematic review, meta-analysis and meta-regression analysis	B	6	Spedali Civili di Brescia, Dipartimento di salute mentale	13,50
ETTORE BEGHI	FARM1235LA	Rationalization of psychopharmacological treatment in adult patients with mental retardation and psychiatric and/or behavioral disturbances, including autistic spectrum disorders. A multicenter randomized pragmatic single-blind study	A	6	IRCCS - Istituto di Ricerche Farmacologiche "Mario Negri", Milano	13.50
BENILDE COSMI	FARM12RNBY	Major haemorrhages (especially intracranial) in elderly subjects (> 80 years) with atrial fibrillation randomized to chronic anticoagulation with warfarin or new oral anticoagulants: data collection through the START-register, computerized register of anticoagulated patients.	A	5	Azienda Ospedaliera-Universitaria S.Orsola-Malpighi, Università di Bologna	13,50
CIRO ESPOSITO	FARM1248JW	Doxycycline long term treatment of dialysis related amyloidosis (DRA) pain and functional impairment	A	7	Divisione di Nefrologia e Dialisi, Fondazione Salvatore Maugeri - Clinica del Lavoro e della Riabilitazione - I.R.C.C.S.- Pavia	14,00
EVA NEGRI	FARM12ZFC3	Frequency and determinants of bevacizumab toxicity in clinical practice	B	1	IRCCS Istituto di Ricerche Farmacologiche "Mario Negri" - Milano	14,00
MARINA GRAZIA BIANCHI	FARM125WLP	Efficacy of an educational intervention addressed to family pediatricians on asthma control in school age children	B	5	IRCCS Istituto di Ricerche Farmacologiche "Mario Negri" - Milano	14

PRINCIPAL INVESTIGATOR	CODICE FARM	TITOLO	AREA	TEMATICA	ISTITUZIONE PROPONENTE	PUNTEGGIO
GRAZIELLA FILIPPINI	FARM12T8JJ	Cochrane systematic reviews of interventions for vasculitis of the nervous system in adults	B	6	U.O. Neuroepidemiologia Fondazione IRCCS Istituto Neurologico Carlo	14,00
PAOLO ANTONIO GROSSI	FARM12ZY39	Efficacy and tolerability of Direct acting antiviral for induction of sustained virologic response in liver transplant recipients infected with HCV (DART-HCV study)	A	9	Università degli Studi dell'Insubria	14,50
YAMUME TSHOMBA	FARM12XSZX	Statins to reduce stroke in endovascular surgery. A meta-analysis	B	6	Fondazione Centro San Raffaele Milano	14,50
MARCO ONOFRI	FARM12J44Z	Impulse control disorder in parkinsonian patients treated with Acamprosate: a double blinded randomized cross over study	A	6	Fondazione Università e centro di eccellenza per le scienze dell'invecchiamento (CeSI), Unità di neurologia, scienze del	14,50
ANDREA ANTINORI	FARM127XLK	Study on dual-therapy with DArunavir/Ritonavir (DRV/r) plus Lamivudine (3TC) versus standard therapy in HIV-positive Naïve patients: DARLAN Study.	A	8	Istituto nazionale malattie infettive, "L. Spallanzani", Roma	14,50
FEDERICA VIGNA-TAGLIANTI	FARM12YZH4	Efficacy of naltrexone, GHB (Gamma-HydroxyButyric acid) and their association with Cognitive-Behavioral Therapy for alcohol dependence: a randomised controlled trial	A	2	Università di Torino, Dipartimento di Scienze Cliniche e Biologiche, Orbassano (TO)	15,00
GIOVANNI DI PERRI	FARM12RC9A	Switch to TDF/3TC/EFV administered thrice weekly in HIV+ patients with stable virological suppression: a randomized and controlled study	A	8	Università di Torino, Dipartimento di Scienze Mediche, Unita di malattie infettive	15,50
GIOVANNI LUCA PAOLO FRASSINETI	FARM127PRE	Phase III study on efficacy of maintenance with bevacizumab vs only follow up after six-month chemotherapy plus bevacizumab in first line in patients with colorectal cancer Running title (max 50 chars) I.T.A.C.A.M.	A	1	Istituto di Ricovero e Cure a Carattere Scientifico, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola	15,50
GABRIELLA FARINA	FARM12N4N9	Randomized Trial of Tailored versus Standard Therapy for the 1st Line Treatment of Patients with Advanced Triple Negative Breast Cancer	A	1	Azienda Ospedaliera Fatebenefratelli E Oftalmico	15,50
ALESSANDRA GENNARI	FARM12N2MB	Development of a dynamic clinical algorithm for the evaluation of the risk of cardiotoxicity in patients undergoing antiangiogenic therapies	B		E.O. Ospedali Galliera Genova	16,00

PRINCIPAL INVESTIGATOR	CODICE FARM	TITOLO	AREA	TEMATICA	ISTITUZIONE PROPONENTE	PUNTEGGIO
GIOVANNI PALLADINI	FARM1298AM	An Open Label Randomized Phase II Trial of Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) versus CyBorD plus Removal of Circulating Amyloidogenic Free Light Chains in Advanced Cardiac AL Amyloidosis (ReFLight protocol, version 1.3, June 11, 2013)	A	1	Università di Pavia	16,00
BARBARA D'AVANZO	FARM127L74	Implementing stepped care for depression with an interactive and participated modality: evaluation of the impact of an educational intervention in general practice	B	5	IRCCS – Istituto di Ricerche Farmacologiche "Mario Negri"	16,00
SERGE MASSON	FARM12HKKK	Optimization of in-hospital management of patients with acute heart failure by the use of natriuretic peptides monitoring: a randomized, multicenter trial (HELP-BNP)	A	10	IRCCS – Istituto di Ricerche Farmacologiche "Mario Negri"	16,00
MARA MORINI	FARM12MB5Y	Impact of innovative or traditional training on antidepressants appropriate use in primary care			Usl Bologna, Dipartimento di assistenza primaria	16,00
GUIDO BERTOLINI	FARM12TAL3	Randomizing continuous INFusion vs. BOlus, to administer <input type="checkbox"/> -lactams in severe, hospital acquired, Gram-negative pneumonia with elevated MIC: multicenter, adaptive, open-label, tWo parallel group,	A	3	IRCCS-Istituto di Ricerche Farmacologiche "Mario Negri"	16,50
TONI IBRAHIM	FARM12BH7S	Multicentric randomized trial to evaluate the efficacy and safety of 12-weekly vs 4-weekly denosumab in patients with bone metastases from breast or prostate cancer treated with 4-weekly denosumab for 6 months	A	1	Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori (Irst) S.R.L. Irccs	16,50
WILMA BARCELLINI	FARM12NY7E	Comparison of the efficacy and safety of standard versus low-dose rituximab in warm autoimmune hemolytic anemia and cold hemagglutinin disease	A	1	U.O. Ematologia 2- U.O.S. Fisiopatologia delle anemie, Fondazione Ca' Granda IRCCS Ospedale Maggiore Policlinico	16,50

PRINCIPAL INVESTIGATOR	CODICE FARM	TITOLO	AREA	TEMATICA	ISTITUZIONE PROPONENTE	PUNTEGGIO
SUSANNA ESPOSITO	FARM12CEHW	Descalation of empiric anti-infective therapy in neonates and infants aged <90 days with sepsis, severe sepsis or septic shock	B	9	Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico	17,00
FRANCESCA PATRIARCA	FARM129L5Y	Prospective, phase II randomized study to compare busulfan-fludarabine to thiotepa-fludarabine reduced-intensity conditioning (RIC) regimens prior to transplantation of allogeneic hematopoietic stem cells for the treatment of myelofibrosis	A	1	Azienda Ospedaliera-Universitaria Udine, Divisione di ematologia e terapie cellulari, Unità 'Carlo Melzi'	17,00
FRANCO MAGGIOLO	FARM12NM85	ALADIN Study. A one-day on, one-day off schedule as maintenance regimen for HAART in fully responsive patients. Version 1.0, April 2013	A	8	Azienda Ospedaliera Papa Giovanni XXIII	17,00
MASSIMO MUSICCO	FARM127B28	Multicenter, randomized, single blind, factorial study on association therapy of memantine and acetyl cholinesterase inhibitors and on transdermal acetyl cholinesterase inhibitors in patients with mild to moderate Alzheimer's disease	A	6	Consiglio Nazionale delle Ricerche, Italia	17,00
ARMANDO SANTORO	FARM12YWX2	Analysis of the cardio- and cerebrovascular toxicologic profile of anti-vegf monoclonal antibody (bevacizumab) treatment in elderly subjects affected by metastatic colorectal cancer (MCRC)	B	1	IRCCS Istituto Clinico Humanitas, Dipartimento Oncologia ed Ematologia	17,50
MAURIZIO D'INCALCI	FARM1235YB	Phase III, multicenter, randomized trial comparing chemotherapy and metformin vs. chemotherapy alone as second or third line treatment in women with epithelial ovarian cancer	A	1	IRCCS – Istituto di Ricerche Farmacologiche "Mario Negri"	17,50
GIOVANNI LANDONI	FARM12ARTS	A meta-analysis of randomized trials on the effect of propofol on mortality	B	6	Fondazione Centro San Raffaele	17,50
EDOARDO DE ROBERTIS	FARM129K8Y	Efficacy of supplementary administration of aerosolized Colistin to the traditional therapeutic protocol for Hospital Acquired Pneumonia caused by Acinetobacter Baumanni.	A	3	Università Federico II di Napoli	17,50

PRINCIPAL INVESTIGATOR	CODICE FARM	TITOLO	AREA	TEMATICA	ISTITUZIONE PROPONENTE	PUNTEGGIO
ROBERTO D'AMICO	FARM12LAP4	Effectiveness and safety of angiogenesis inhibitors in patients affected by age-related macular degeneration (AMD): a systematic review	B	6	Università di Modena e Reggio Emilia	18,00
IVANO RIVA	FARM12F2XJ	Pharmacological treatment of open angle glaucoma and ocular hypertension. Comparison of efficacy and safety between formulations with (preserved) or without preservatives (preservative free): systematic review and meta-analysis.	B	6	Università degli Studi di Brescia	18,25
CALOGERO CAMMA'	FARM12CWEX	Evaluation of Adverse events, with particular regard to cardiotoxicity and cardiovascular risk, of Sorafenib in patients with hepatocellular carcinoma (HCC) on cirrhosis	B	1	Università degli Studi di Palermo, Dipartimento BioMedico di Medicina Interna e Specialistica, Sezione di Gastroenterologia	19,00
CRISTIANA VITALE	FARM124FRS	Monitoring of drug utilisation following training programs on appropriate prescription in general practitioners.	B	5	IRCCS San Raffaele Pisana	19,00
LUCA CABRINI	FARM12C2WK	A network meta-analysis of randomized trials performed in intensive care units on the effects of sedative agents on mortality.	B	6	Maieutics Medical Research Foundation - Direzione Generale	19,00
ANDREA COLLI	FARM12XTP12	Systematic Review on efficacy and risk-benefit profile of dual antiplatelet therapy with Clopidogrel and acetylsalicylic acid in patients undergoing coronary artery bypass graft	B	6	Università degli Studi di Padova	19,50
ANITA CONFORTI	FARM12T928	Medication reconciliation: study on complex patients and role of the general practitioner	B	5	Università degli Studi di Verona	19,50
NICOLA PETROSILLO	FARM128TPZ	High prevalence of multi-drug resistant microorganisms in Intensive Care Unit and frequency of the de-escalation therapy: is there a link?	B	9	Istituto nazionale malattie infettive, "L. Spallanzani", Roma	19,50

PRINCIPAL INVESTIGATOR	CODICE FARM	TITOLO	AREA	TEMATICA	ISTITUZIONE PROPONENTE	PUNTEGGIO
GIANCARLO LOGROSCINO	FARM1225HT	Role of treatment with two fixed doses of erythropoietin biosimilars on the risk of symptomatic cerebrovascular events, dementia and seizures in patients with renal insufficiency terminale_ (Role of two fixed doses of biosimilar erithropoietins on the risk of cerebrovascular events, seizures and dementia in people with end Stage kidney disease)	A	4	Università degli Studi di Bari	20,00
MASSIMILIANO GRECO	FARM122C9E	A network meta-analysis of randomized trials on all anesthesia techniques in cardiac surgery.	B	6	Maieutics Medical Research Foundation	20,50
ORIANA NANNI	FARM12FH85	Potential Biomarkers of Antiangiogenic Therapy-induced Cardiotoxicity	B	1	Istituto scientifico romagnolo per lo studio e la cura dei tumori	21,00
GIOVANNI ADDOLORATO	FARM124L5Y	Evaluation of the efficacy of Baclofen and of other drugs currently approved in Italy for the treatment of alcohol dependence in hospitalized patients in residential setting	A	2	Ospedale "A. Gemelli" Università Cattolica di Roma, Dipartimento di Medicina Interna	21,00
ANTONIO PRETI	FARM122RHB	Systematic review on the recurrent brief depression	B	6	Università degli Studi di Cagliari, Dipartimento di Sanità Pubblica e Medicina Clinica e Molecolare	21,50
ALESSANDRO FILLA	FARM129WW4	A multicenter, randomized, double blind, placebo controlled trial to assess the efficacy, safety and tolerability of Dantrolene in Spinocerebellar Ataxia type 2.	A	7	Università degli Studi di Napoli "Federico II" Dipartimento di Neuroscienze e Scienze Odontostomatologiche e Riproduttive	22,25
GIANLUCA TRIFIRO'	FARM12JEW5	Assessment of the benefit-risk profile of the incretins as compared to other antidiabetics through a multi-Regional database network	B	3	Policlinico Universitario "G. Martino", Dipartimento di Medicina clinica e Sperimentale, Università di Messina	22,50
ALBERTO DONZELLI	FARM12LMX	Impact of an information and education programme for the General Practitioners (GPs) and through them, for the patients, focused on the appropriateness of the drug use and ewpenditure, integrated with non-pharmacological strategies	B	5	ASL di Milano	22,50

PRINCIPAL INVESTIGATOR	CODICE FARM	TITOLO	AREA	TEMATICA	ISTITUZIONE PROPONENTE	PUNTEGGIO
LITAL HOLLANDER	FARM12HX8B	Thromboprophylaxis in hip and knee arthroplasty . Pre versus post-operative administration of antithrombotic drugs	B	6	IRCCS Istituto di ricerche farmacologiche "Mario Negri"	23,00
NORBERTO CAU	FARM12EF9A	Prescriptive appropriateness of cardiovascular drugs: a training programme for General Practitioners in Lazio region in a gender perspective	B	5	LAZIOSANITA'- Agenzia di Sanità Pubblica della Regione Lazio, (Laziosanità-ASP)	23,50
DARIO GIUGLIANO	FARM12HTT5	Safety and cardiovascular risk of antidiabetic drugs in the real world: observational Italian study on the comparison between incretins + metformin vs sulfonylureas + metformin (SUNRISE)	B	3	Seconda Università di Napoli	26,00
LUIGI NALDI	FARM123BAE	Biomarkers in the prediction of relapse after discontinuation of antagonists of tumor necrosis factor-alpha in psoriasis: a multicenter clinical trial of randomized treatment suspension	A	1	Centro Studi GISED	30,00
CARMELO IACONO	FARM12LNZS	Long-term care in cancer: information and education on drug use for the cancer control community - oncologists, family doctors, local health units, specialist cancer centers, voluntary organizations and patients.	B	5	Fondazione AIOM	30,00
SPINELLO ANTINORI	FARM12WKJ9	An antifungal stewardship program for the appropriate management of invasive fungal infections	B	8	Università di Milano, Dipartimento di Scienze Biomediche e Cliniche "Luigi Sacco"	30,00
CHIARA LIZ PANDOLFINI	FARM12M47B	Evaluation of the efficacy of educational interventions in improving the rational use of antibiotics in pharyngotonsillitis and acute otitis media	B	5	IRCCS Istituto di Ricerche Farmacologiche "Mario Negri"	30,75
MARIA RUCCIA	FARM12P84M	Efficacy assessment of training courses toward the General Practitioners (GP) aimed to improve the appropriateness of prescriptions for COPD in Puglia Region, especially for gender medicine	B	5	Agenzia Regionale Sanitaria – Regione Puglia	32,25